Rigel Pharmaceuticals RIGL Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's other accrued liabilities?
- Rigel Pharmaceuticals (RIGL) reported other accrued liabilities of $9.67M in Q1 2026.
- How has Rigel Pharmaceuticals's other accrued liabilities changed year-over-year?
- Rigel Pharmaceuticals's other accrued liabilities increased by 30.0% year-over-year, from $7.44M to $9.67M.
- What is the long-term trend for Rigel Pharmaceuticals's other accrued liabilities?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's other accrued liabilities has grown at a 0.8% compound annual growth rate (CAGR), from $11.01M to $11.47M.